Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Berry

Showing results (31-40 of 146) with videos related to

Pageof 15
Sort By:
International Journal of Cancer|February 22, 2017
Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, CanadaKatarzyna J Jerzak, Scott Berry, Yoo-Joung Ko, et al.
Ecancermedicalscience|March 5, 2024
The differential needs and expectations from general practitioners in oncology between high-income countries and low- and-middle-income countries: results from a survey of Canadian and Nepali oncologistsBishal Gyawali, Bishesh Sharma Poudyal, Laura M Carson, et al.
Current Medical Research and Opinion|June 11, 2013
Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritisMarc C Hochberg, Scott Berry, Kristine Broglio, et al.
AJPM Focus|June 17, 2024
Wastewater Surveillance for Xylazine in KentuckyChris Delcher, Dana Quesinberry, Soroosh Torabi, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's diseaseAndrew Satlin, Jinping Wang, Veronika Logovinsky, et al.
Alzheimer'S Research & Therapy|September 29, 2018
Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)Elizabeth Finger, Scott Berry, Jeffrey Cummings, et al.
Diabetes Technology & Therapeutics|May 15, 2014
A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulinDavid H Manner, Junxiang Luo, Yongming Qu, et al.
Disaster Medicine and Public Health Preparedness|February 18, 2025
COVID-19 Risk and Crisis Communication Challenges and Opportunities: Qualitative Insights from Rural Wastewater Surveillance PartnersSavannah G Tucker, Beverly May, Matthew Liversedge, et al.
Journal of Diabetes Science and Technology|January 9, 2013
Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulationsZachary Skrivanek, Scott Berry, Don Berry, et al.
JCO Global Oncology|May 4, 2023
Training General Practitioners in Oncology: Lessons Learned From a Cross-Sectional Survey of GPOs in CanadaBishal Gyawali, Laura Mae Carson, Sian Shuel, et al.
Pageof 15

Showing results (31-40 of 146) with videos related to

Sort By:
Pageof 15
International Journal of Cancer|February 22, 2017
Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, CanadaKatarzyna J Jerzak, Scott Berry, Yoo-Joung Ko, et al.
Ecancermedicalscience|March 5, 2024
The differential needs and expectations from general practitioners in oncology between high-income countries and low- and-middle-income countries: results from a survey of Canadian and Nepali oncologistsBishal Gyawali, Bishesh Sharma Poudyal, Laura M Carson, et al.
Current Medical Research and Opinion|June 11, 2013
Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritisMarc C Hochberg, Scott Berry, Kristine Broglio, et al.
AJPM Focus|June 17, 2024
Wastewater Surveillance for Xylazine in KentuckyChris Delcher, Dana Quesinberry, Soroosh Torabi, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's diseaseAndrew Satlin, Jinping Wang, Veronika Logovinsky, et al.
Alzheimer'S Research & Therapy|September 29, 2018
Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)Elizabeth Finger, Scott Berry, Jeffrey Cummings, et al.
Diabetes Technology & Therapeutics|May 15, 2014
A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulinDavid H Manner, Junxiang Luo, Yongming Qu, et al.
Disaster Medicine and Public Health Preparedness|February 18, 2025
COVID-19 Risk and Crisis Communication Challenges and Opportunities: Qualitative Insights from Rural Wastewater Surveillance PartnersSavannah G Tucker, Beverly May, Matthew Liversedge, et al.
Journal of Diabetes Science and Technology|January 9, 2013
Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulationsZachary Skrivanek, Scott Berry, Don Berry, et al.
JCO Global Oncology|May 4, 2023
Training General Practitioners in Oncology: Lessons Learned From a Cross-Sectional Survey of GPOs in CanadaBishal Gyawali, Laura Mae Carson, Sian Shuel, et al.
Pageof 15